SCHEMBL703377

SCHEMBL703377

CC(=CCC(=O)O)CCC1=C(C)CCCC1(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 6/20 0.60
RARG P13631 6/20 0.60
RXRA P19793 6/20 0.60
RARA P10276 5/20 0.60
TRPA1 O75762 3/20 0.53
ALOX15 P16050 2/20 0.52
ALOX5 P09917 1/20 0.52
ALDH1A1 P00352 5/20 0.46
MAPT P10636 5/20 0.46
GAA P10253 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PLA2G1B P04054 1/20 0.46
PLA2G2A P14555 1/20 0.46
POLK Q9UBT6 1/20 0.46
BLM P54132 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP1A2 P05177 2/20 0.43
HAO1 Q9UJM8 1/20 0.41
PTGS1 P23219 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9202781 1.00 RARB (0.60) RARBRARGRXRARARATRPA1
SCHEMBL703376 1.00 RARB (0.60) RARBRARGRXRARARATRPA1
SCHEMBL24475285 0.90 RARB (0.58) RARBRARGRXRARARATRPA1
SCHEMBL9016204 0.88 ALOX5 (0.59) RARBRARGRXRARARATRPA1
SCHEMBL9016206 0.88 ALOX5 (0.59) RARBRARGRXRARARATRPA1
SCHEMBL10044151 0.86 RARB (0.54) RARBRARGRXRARARATRPA1
SCHEMBL18084341 0.86 RARB (0.54) RARBRARGRXRARARATRPA1
SCHEMBL1105236 0.86 RARB (0.54) RARBRARGRXRARARATRPA1
SCHEMBL16670830 0.85 RARB (0.56) RARBRARGRXRARARATRPA1
SCHEMBL13554229 0.85 RARB (0.56) RARBRARGRXRARARATRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217362-A1 REDUCTION BY A SILANE IN THE PRESENCE OF ZINC CATALYST Firmenich SA (CH) 2023-08-02 EP claimed
WO-2022112118-A1 REDUCTION BY A SILANE IN THE PRESENCE OF ZINC CATALYST FIRMENICH SA (CH) 2022-06-02 WO claimed
EP-3060546-B1 PROCESSES FOR THE PREPARATION OF UNSATURATED ESTERS INT FLAVORS & FRAGRANCES INC (US) 2019-02-13 EP claimed
EP-4217362-B1 REDUCTION BY A SILANE IN THE PRESENCE OF ZINC CATALYST FIRMENICH & CIE (CH) 2026-03-18 EP disclosed
US-20240010585-A1 REDUCTION BY A SILANE IN THE PRESENCE OF ZINC CATALYST FIRMENICH SA (CH) 2024-01-11 US disclosed
US-11858948-B2 Hydrogenation of carbonyls with tetradentate PNNP ligand ruthenium complexes FIRMENICH SA (CH) 2024-01-02 US disclosed
EP-4217362-A1 REDUCTION BY A SILANE IN THE PRESENCE OF ZINC CATALYST Firmenich SA (CH) 2023-08-02 EP disclosed
WO-2022112118-A1 REDUCTION BY A SILANE IN THE PRESENCE OF ZINC CATALYST FIRMENICH SA (CH) 2022-06-02 WO disclosed
EP-3700914-B1 HYDROGENATION OF CARBONYLS WITH TETRADENTATE PNNP LIGAND RUTHENIUM COMPLEXES FIRMENICH & CIE (CH) 2022-02-02 EP disclosed
US-20200399299-A1 HYDROGENATION OF CARBONYLS WITH TETRADENTATE PNNP LIGAND RUTHENIUM COMPLEXES FIRMENICH SA (CH) 2020-12-24 US disclosed
EP-3700914-A1 HYDROGENATION OF CARBONYLS WITH TETRADENTATE PNNP LIGAND RUTHENIUM COMPLEXES Firmenich SA (CH) 2020-09-02 EP disclosed
EP-1868965-A1 HYDROGENATION OF ESTERS WITH RU/TETRADENTATE LIGANDS COMPLEXES FIRMENICH SA (CH) 2007-12-26 EP disclosed
EP-1868964-A1 HYDROGENATION OF ESTERS WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH SA (CH) 2007-12-26 EP disclosed
EP-1773799-A1 PROCESS FOR THE PREPARATION OF OPTICALLY-ACTIVE COMPOUNDS Givaudan SA (CH) 2007-04-18 EP disclosed
WO-2006106484-A1 HYDROGENATION OF ESTERS WITH RU/TETRADENTATE LIGANDS COMPLEXES FIRMENICH SA (CH) 2006-10-12 WO disclosed
WO-2006106483-A1 HYDROGENATION OF ESTERS WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH SA (CH) 2006-10-12 WO disclosed
WO-2006010287-A1 PROCESS FOR THE PREPARATION OF OPTICALLY-ACTIVE COMPOUNDS GIVAUDAN SA (CH) 2006-02-02 WO disclosed
EP-0525579-B1 Process for preparing substituted hexemic acids GIVAUDAN ROURE INT (CH) 1995-09-20 EP disclosed
US-5292902-A Process for the manufacture of odorants and intermediates used therein GIVAUDAN-ROURE CORPORATION (US) 1994-03-08 US disclosed
EP-0525579-A2 Process for preparing substituted hexemic acids GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) 1993-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240010585-A1 REDUCTION BY A SILANE IN THE PRESENCE OF ZINC CATALYST HDAC10, AKR1B10, ADH1A RARB 3085/4885RARG 3640/4885RXRA 4166/4885
US-11858948-B2 Hydrogenation of carbonyls with tetradentate PNNP ligand ruthenium complexes ADH1C, ADH1A, ADH5 RARB 2983/4885RARG 2648/4885RXRA 1872/4885
US-20200399299-A1 HYDROGENATION OF CARBONYLS WITH TETRADENTATE PNNP LIGAND RUTHENIUM COMPLEXES ADH1C, ADH1A, ADH5 RARB 2983/4885RARG 2648/4885RXRA 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.